secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2022-04-01T23:59:59+00:00
Accession:  0001654954-22-004477
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Monopar Therapeutics Co-Founder and CSO Dr. Andrew Mazar resigns effective April 8, 2022
--------------------------------------------------------------------------------

- Dr. Andrew P. Mazar resigns as EVP of R&D, Chief Scientific Officer, and Board member.
- Resignation effective April 8, 2022; no replacement announced.
- Dr. Mazar was a Co-Founder of the company.
- Monopar's common stock trades on Nasdaq under ticker MNPR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000165495422004477/0001654954-22-004477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000165495422004477/mnpr_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-004477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer